Probiomed has been acquired by Sanfer
The shareholders of Probiomed S.A. de C.V. have sold the company to Laboratorios Sanfer.
Probiomed was founded in 1970 and is a vertically integrated developer, manufacturer and marketer of pharmaceutical and biopharmaceutical products. The company has three production plants and one of the most advanced R&D platforms in the region. The R&D team has 46 engineers who have developed and launched over 120 products, 14 of which were biopharmaceuticals.
Sanfer, with over 80 years of history, is one of the leading companies in the Mexican pharmaceutical market. It participates in more than 10 therapeutic areas, including infectiology, algology, cardiology, gastroenterology, central nervous system, metabolic syndrome, gynecology, urology, oncology, over-the-counter products and animal health products for all types of species.
Oaklins’ team in Mexico acted as the financial advisor to Probiomed in the debt restructuring of US$120 million under Chapter 11 “Concurso Mercantil” in Mexico, as well as in the structuring of the acquisition by Sanfer, resulting in an equity injection of US$30 million.
Talk to the deal team
Related deals
Dolmans Landscaping Group has welcomed Foreman Capital as a new shareholder to support further growth
Dolmans Landscaping Group, a leading full-service provider of landscaping services, has welcomed Foreman Capital as a new shareholder. By partnering with Foreman Capital, which has extensive experience in building stronger companies in the maintenance of public spaces, Dolmans can accelerate its growth trajectory across core verticals and further professionalize the business.
Learn moreRare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Learn moreBackspin has completed a mandatory public tender offer for the shares of Spindox
Backspin S.p.A. has completed a mandatory public tender offer for Spindox S.p.A.
Learn more